Summary
Cysteamine (1.95 or 3.90 mM/kg) administered subcutaneously (sc) markedly decreased the open-field activity of the rats, while the structurally related amino acid cysteine had only minor influence. Cysteamine (1.95 or 3.90 mM/kg) reduced the noradrenaline and increased the dopamine and dihydroxyphenyl acetic acid (DOPAC) levels in the hypothalamus. In striatum the drug decreased both the noradrenaline (1.95 or 3.90 mM/kg) and dopamine (3.90 mM/kg) levels without influencing the DOPAC content. Neither the hypothalamic nor the striatal catecholamines are influenced by administration of equimolar doses of cysteine.
Cysteamine (1.95 or 3.90 mM/kg) decreased the somatostatin levels both in the hypothalamus and in the striatum without influencing neuropeptide Y (NPY) and corticotropin releasing hormone (CRH) concentrations. Cysteine administered in equimolar doses did not influence the peptide levels in these brain structures.
These data suggest that the cysteamine-induced behavioural changes are related to the decrease of brain noradrenaline and somatostatin concentrations. The structurally related amino acid cystein does not influence the behaviour or the central monoaminergic and peptidergic concentrations in the hypothalamus and striatum of rats.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bakhit C, Swerdlow N (1986) Behavioral changes following central injection of cysteamine in rats. Brain Res 365: 159–163
Bannai S (1984) Transport of cysteine and cystine in mammalian cells. Biochim Biophys Acta 779: 289–306
Bjartell A, Ekman R, Sundler F (1987) γ-MSH-like immunoreactivity in porcine pituitary and adrenal medulla. An immunochemical and immunocytochemical study. Reg Pept 19: 291–306
Chatta GK, Beal MF (1987) Effect of cysteamine on somatostatin and neuropeptide Y in rat striatum and cortical synaptosomes. Brain Res 40: 359–364
Chronwall BM, Chase TN, O'Donohue TL (1984) Coexistence of neuropeptide Y and somatostatin in rat and human cortical and rat hypothalamic neurons. Neurosci Lett 52: 213–217
Cooper JR, Bloom FE, Roth RH (1978) The biochemical basis of neuropharmacology, chapter 6. Oxford University Press, New York, pp 102–160
DiLiberto EJ Jr, DiStefano V, Crispin-Smith J (1973) Mechanism and kinetics of the inhibition of dopamine-Β-hydroxylase by 2-mercaptoethylguanidine. Biochem Pharmacol 22: 2961–2972
Engel JA, Johannessen K, Liljequist S, Goldstein M (1986) Activation of α2-adrenoreceptors enhances haloperidol-induced suppression of operant behaviour. J Neural Transm 66: 107–120
Eriksson BM, Persson BA (1982) Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J Chromatogr 228: 143–154
Heilig M, Wahlestedt C, Widerlöv E (1988) Neuropeptide Y (NPY)-induced activity suppression in the rat: evidence for NPY receptor heterogeneity and for interaction with α-adrenoceptors. Eur J Pharmacol 157: 205–213
Lundberg JM, Terenius L, Hökfelt T, Martling CR, Tatemoto K, Mutt V, Polak JM, Bloom S, Goldstein M (1982) Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 116: 477–480
Magnusson O, Nilsson LB, Westerlund D (1980) Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography-electrochemical detection system. J Chromatogr 221: 237–247
Meister A (1986) Glutathione: metabolism, transport and the effects of selective modifications of cellular glutathione levels. In: Holmgren A, Bråndén CI, Jörnvall H, Sjöberg BM (eds) Thioredoxin and glutaredoxin systems. Structure and function. Raven Press, New York, pp 339–348
Millard WJ, Sagar SM, Laudis DMD, Martin JB (1982) Cysteamine: a potent and specific depletor of pituitary prolactin. Science 217: 452–454
Orloff S, Butler JDeB, Towne D, Mukherjee AB, Schulman JD (1981) Pantetheinase activity and cysteamine content in cystinotic and normal fibroblasts and leukocytes. Pediatr Res 15: 1063–1067
Palkovits M, Brownstein MJ, Eiden LE, Beinfeld MC, Russel J, Arimura A, Szabo S (1982) Selective depletion of somatostatin in rat brain by cysteamine. Brain Res 240: 178–180
Rivier C, Vale W (1985) Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology 117: 2478–2482
Sagar SM, Landry D, Millard WJ, Badger TM, Arnold MA, Martin JB (1982) Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine. J Neurosci 2: 225–231
Scott JS, Lakin CA, Oliver JR (1987) The effect of cysteamine, cystamine and the structurally related compounds taurine, N-acetyl-cysteine and D-penicillamine on plasma prolactin levels in normal and estrogen-primed hyperprolactinemic rats. Endocrinology 121: 812–818
Steranka LR, Rhind AW (1987) Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. Eur J Pharmacol 133: 191–197
Sundler F, Håkanson R, Ekblad E, Uddman R, Wahlestedt C (1986) Neuropeptide Y in peripheral adrenergic and enteric nervous systems. Ann Rev Cytol 102: 243–269
Szabo S, Horner HC, Maull H, Schnoor J, Chiueh CG, Palkovits M (1987) Biochemical changes in tissue catecholamines and serotonin in duodenal ulceration caused by cysteamine or proprionitrile in the rat. J Pharmacol Exp Therap 240: 871–878
Szabo S, Reichlin S (1981) Somatostatin in rat tissues is depleted by cysteamine administration. Endocrinology 109: 255–257
Telegdy G (1987) Neuropeptides and brain function. In: van Wimersma Greidanus TjB (ed) Frontiers of hormone research, vol 15. Karger, Basel, pp 1–323
Terry LC, Craig R (1985) Cysteamine effects on monoamines, dopamine-Β-hydroxylase and the hypothalamic-pituitary axis. Neuroendocrinology 41: 467–475
Vécsei L, Balázs M, Bollók I, Telegdy G (1985) Selective decrease of hypothalamic noradrenaline by cysteamine. Arch Int Pharmacodyn 274: 125–128
Vécsei L, Bollók I, Telegdy G (1983) Comparative studies with cyclic and linear somatostatin on active avoidance behaviour and open-field activity in rats. Acta Physiol Hung 61: 43–49
Vécsei L, Király Cs, Bollók I, Nagy A, Varga J, Penke B, Telegdy G (1984) Comparative studies with somatostatin and cysteamine in different behavioral tests in rats. Pharmacol Biochem Behav 21: 833–837
Wallengren J, Ekman R, Sundler F (1987) Occurrence and distribution of neuropeptides in the human skin. Acta Derm Venerol (Stockholm) 67: 185–192
Widerlöv E, Lewander T (1978) The relationship between amphetamine antagonism and depletion of brain catecholamines by alpha-methyl-p-tyrosine in rats. Naunyn Schmiedebergs Arch Pharmacol 304: 125–134
Widerlöv E, Lindström LH, Wahlestedt C, Ekman R (1988) Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiat Res 22: 69–79
Widerlöv E, Ekman R, Jensen L, Borglund L, Nyman K (1989) Arqinine vasopressin, but corticotropin releasing factor, is a potent stimulator of adrenocorticotropic hormone following electroconvulsive treatment. J Neural Transm 75: 101–109
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vécsei, L., Ekman, R., Alling, C. et al. Influence of cysteamine and cysteine on open-field behaviour, and on brain concentrations of catecholamines, somatostatin, neuropeptide Y, and corticotropin releasing hormone in the rat. J. Neural Transmission 78, 209–220 (1989). https://doi.org/10.1007/BF01249230
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01249230